Search research articles
Contact Us
Filters
Showing results (111-120 of 280) with videos related to
Page
of 28
Sort By:
The Medical Journal of Australia
|
September 27, 2006
Diabetes guidelines: easier to preach than to practise?
Wendy Bryant, Jerry R Greenfield, Donald J Chisholm, et al.
Obesity Research
|
April 12, 2002
Regional intra-subject variability in abdominal adiposity limits usefulness of computed tomography
Jerry R Greenfield, Katherine Samaras, Donald J Chisholm, et al.
Journal of the American Geriatrics Society
|
June 4, 2009
Weight maintenance in hospitalized geriatric patients treated with beta-blockers
Paul Lee, Jerry R Greenfield, Richard O Day, et al.
Anaesthesia and Intensive Care
|
April 8, 2010
New insulin analogues and perioperative care of patients with type 1 diabetes
J Killen, K Tonks, J R Greenfield, et al.
Nutrients
|
March 27, 2015
L-glutamine and whole protein restore first-phase insulin response and increase glucagon-like peptide-1 in type 2 diabetes patients
Dorit Samocha-Bonet, Don J Chisholm, Jens J Holst, et al.
Drug Safety
|
October 23, 2020
Potential Safety Issues with Use of Sodium-Glucose Cotransporter 2 Inhibitors, Particularly in People with Type 2 Diabetes and Chronic Kidney Disease
Tamara Y Milder, Sophie L Stocker, Richard O Day, et al.
Drug Safety
|
October 17, 2023
Sodium-Glucose Cotransporter 2 Inhibitor-Associated "Ketoacidosis" Versus "Diabetic Ketoacidosis": The Importance of Accurate Terminology
Tamara Y Milder, David A Milder, Jerry R Greenfield, et al.
International Journal of Obesity (2005)
|
May 30, 2012
Formoterol, a highly β2-selective agonist, increases energy expenditure and fat utilisation in men
P Lee, R O Day, J R Greenfield, et al.
Radiology
|
September 1, 1975
Compartmental evaluation of osteoarthritis of the knee. A comparative study of available diagnostic modalities
R H Thomas, D Resnick, N P Alazraki, et al.
Internal Medicine Journal
|
May 21, 2020
Should the cardio-protective properties of sodium-glucose cotransporter 2 inhibitors dictate therapeutic decision-making in patients with type 2 diabetes
Tamara Y Milder, Richard O Day, Sophie L Stocker, et al.
Page
of 28
Search research articles
Search
Showing results (111-120 of 280) with videos related to
Sort By:
Page
of 28
The Medical Journal of Australia
|
September 27, 2006
Diabetes guidelines: easier to preach than to practise?
Wendy Bryant, Jerry R Greenfield, Donald J Chisholm, et al.
Obesity Research
|
April 12, 2002
Regional intra-subject variability in abdominal adiposity limits usefulness of computed tomography
Jerry R Greenfield, Katherine Samaras, Donald J Chisholm, et al.
Journal of the American Geriatrics Society
|
June 4, 2009
Weight maintenance in hospitalized geriatric patients treated with beta-blockers
Paul Lee, Jerry R Greenfield, Richard O Day, et al.
Anaesthesia and Intensive Care
|
April 8, 2010
New insulin analogues and perioperative care of patients with type 1 diabetes
J Killen, K Tonks, J R Greenfield, et al.
Nutrients
|
March 27, 2015
L-glutamine and whole protein restore first-phase insulin response and increase glucagon-like peptide-1 in type 2 diabetes patients
Dorit Samocha-Bonet, Don J Chisholm, Jens J Holst, et al.
Drug Safety
|
October 23, 2020
Potential Safety Issues with Use of Sodium-Glucose Cotransporter 2 Inhibitors, Particularly in People with Type 2 Diabetes and Chronic Kidney Disease
Tamara Y Milder, Sophie L Stocker, Richard O Day, et al.
Drug Safety
|
October 17, 2023
Sodium-Glucose Cotransporter 2 Inhibitor-Associated "Ketoacidosis" Versus "Diabetic Ketoacidosis": The Importance of Accurate Terminology
Tamara Y Milder, David A Milder, Jerry R Greenfield, et al.
International Journal of Obesity (2005)
|
May 30, 2012
Formoterol, a highly β2-selective agonist, increases energy expenditure and fat utilisation in men
P Lee, R O Day, J R Greenfield, et al.
Radiology
|
September 1, 1975
Compartmental evaluation of osteoarthritis of the knee. A comparative study of available diagnostic modalities
R H Thomas, D Resnick, N P Alazraki, et al.
Internal Medicine Journal
|
May 21, 2020
Should the cardio-protective properties of sodium-glucose cotransporter 2 inhibitors dictate therapeutic decision-making in patients with type 2 diabetes
Tamara Y Milder, Richard O Day, Sophie L Stocker, et al.
Page
of 28